drugset / Trial / NCT00248547

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547

Completed 40 enrolled OHSU Knight Cancer Institute
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized clinical trial is studying aprepitant, ondansetron, and dexamethasone to see how well they work compared to placebo, ondansetron, and dexamethasone in preventing nausea and vomiting in patients who are undergoing a stem cell transplant.

Timeline

Start
2004-05
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aprepitant Other / unclassified 80 mg Oral
Comparator Dexamethasone Small molecule Oral
Comparator Ondansetron Other / unclassified 8 mg Oral

Indications